sorafenib has been researched along with ferrostatin-1 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ferrostatin-1) | Trials (ferrostatin-1) | Recent Studies (post-2010) (ferrostatin-1) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 176 | 0 | 175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Chen, JN; Cheng, L; He, YZ; Li, QY; Li, T; Liu, G; Qin, TS; Sun, YX; Wei, Y; Yao, D; Zhang, GJ | 1 |
| Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC | 1 |
| Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H | 1 |
1 review(s) available for sorafenib and ferrostatin-1
| Article | Year |
|---|---|
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53 | 2020 |
2 other study(ies) available for sorafenib and ferrostatin-1
| Article | Year |
|---|---|
Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Glutathione Peroxidase; Humans; Intracellular Space; Molecular Docking Simulation; Protein Conformation; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship; Urea; Urinary Bladder Neoplasms | 2020 |
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib | 2013 |